Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (10,2 Mio. €): Gesundheitsinitiativen bei Psoriasis und Psoriasis-Arthritis ConsoRTium Europäische Staaten Hor01.07.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Gesundheitsinitiativen bei Psoriasis und Psoriasis-Arthritis ConsoRTium Europäische Staaten
Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal: these represent critical, contemporary unmet clinical needs. HIPPOCRATES is a multi-centre consortium, with 26 world-class partners that have clinical, scientific, data analytics, ethics, patient participation and pharmaceutical industry expertise. We will address these needs. Clinical phenotypic data from multiple established, and de novo PsA cohorts combined with a unique library of bio- samples, images, and data derived therefrom, will be curated and catalogued for optimal evaluation and use. HIPPOCRATES will analyse these multi-structured datasets that traverse the disease timeline, from cutaneous psoriasis, early PsA, first therapeutic and first biologic choice. Through machine learning and other AI techniques, we will: (1) Identify molecular signals associated with the development of PsA in patients with psoriasis, so presaging PsA prevention studies; (2) Create a diagnostic algorithm for early PsA diagnosis in patients with cutaneous psoriasis or early undifferentiated inflammatory arthritis; (3) Generate biomarker algorithms, including clinical, imaging and molecular polyomic moieties, to predict disease progression and identify endotypes permitting precision treatment with existing (methotrexate, and TNF or IL-17 inhibitor) treatments and novel therapeutic regimes; (4) Elucidate the molecular basis of PsA to facilitate future drug discovery; (5) Develop diagnostic digital tools for use in clinical settings. With highly aligned academic/clinical, SME and EFPIA partners, including involvement from existing IMI programmes and competitive international associations, HIPPOCRATES will oversee the development of a sustainable infrastructure to support PsA research and improve PsA patient outcomes.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| 675.000 € | |
| Abbvie Inc. | 0,00 € |
| 0,00 € | |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | 540.750 € |
| EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY | 83.125 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 1.132.945 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 134.375 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Katholieke Universiteit Leuven | 448.400 € |
| King's College London | 100.000 € |
| Kungliga Tekniska Hoegskolan | 519.829 € |
| NOVARTIS PHARMA AG | 0,00 € |
| Neoteryx Ltd. | 0,00 € |
| Oxford Biodynamics plc | 249.375 € |
| Pfizer Ltd. | 0,00 € |
| Region Hovedstaden | 100.000 € |
| SIB SWISS INSTITUTE OF BIOINFORMATICS | 585.476 € |
| Stichting Amsterdam UMC | 130.000 € |
| 221.250 € | |
| THE European Institute for Innovation Through Health Data | 225.000 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 729.686 € |
| The University of Manchester | 765.426 € |
| Trajan Scientific Europe Ltd. | 195.000 € |
| UCB Biopharma | 0,00 € |
| 501.063 € | |
| UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN | 1.492.441 € |
| Universita Cattolica Del Sacro Cuore | 130.000 € |
| University of Glasgow | 627.590 € |
| VIB VZW | 624.261 € |
Quelle: https://cordis.europa.eu/project/id/101007757
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "ATTUROS Ltd. - EU-Förderung (10,2 Mio. €): Gesundheitsinitiativen bei Psoriasis und Psoriasis-Arthritis ConsoRTium Europäische Staaten"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
